CA2512147C - Aqueous extract of red vine leave and use thereof for improving blood circulation - Google Patents
Aqueous extract of red vine leave and use thereof for improving blood circulation Download PDFInfo
- Publication number
- CA2512147C CA2512147C CA2512147A CA2512147A CA2512147C CA 2512147 C CA2512147 C CA 2512147C CA 2512147 A CA2512147 A CA 2512147A CA 2512147 A CA2512147 A CA 2512147A CA 2512147 C CA2512147 C CA 2512147C
- Authority
- CA
- Canada
- Prior art keywords
- extract
- use according
- red vine
- composition
- vine leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000978499 Brunnichia ovata Species 0.000 title claims abstract description 31
- 239000006286 aqueous extract Substances 0.000 title claims abstract description 20
- 230000017531 blood circulation Effects 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 21
- 210000003141 lower extremity Anatomy 0.000 claims abstract description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001301 oxygen Substances 0.000 claims abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- 235000007882 dietary composition Nutrition 0.000 claims abstract description 10
- 201000002282 venous insufficiency Diseases 0.000 claims description 49
- 201000002816 chronic venous insufficiency Diseases 0.000 claims description 48
- 239000000284 extract Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 21
- 230000004089 microcirculation Effects 0.000 claims description 14
- 229930003935 flavonoid Natural products 0.000 claims description 10
- 150000002215 flavonoids Chemical class 0.000 claims description 10
- 235000017173 flavonoids Nutrition 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 28
- 229940068196 placebo Drugs 0.000 description 28
- 210000003423 ankle Anatomy 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 244000309466 calf Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 7
- 206010030124 Oedema peripheral Diseases 0.000 description 6
- 241000219095 Vitis Species 0.000 description 4
- 235000009392 Vitis Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007941 film coated tablet Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000050 nutritive effect Effects 0.000 description 4
- 238000002496 oximetry Methods 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 208000005230 Leg Ulcer Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020919 Hypervolaemia Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010048591 Post thrombotic syndrome Diseases 0.000 description 1
- 240000000353 Ruscus aculeatus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940061241 butcher's broom preparation Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- HBKPGGUHRZPDIE-UHFFFAOYSA-N ethoxy-methoxy-sulfanylidene-(2,4,5-trichlorophenoxy)-$l^{5}-phosphane Chemical compound CCOP(=S)(OC)OC1=CC(Cl)=C(Cl)C=C1Cl HBKPGGUHRZPDIE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229940045809 horse chestnut seed Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000005592 lipodermatosclerosis Diseases 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02029107A EP1435242A1 (en) | 2002-12-31 | 2002-12-31 | Method of improvement of blood circulation |
| EP02029107.6 | 2002-12-31 | ||
| PCT/EP2003/014147 WO2004058280A1 (en) | 2002-12-31 | 2003-12-12 | Method of improvement of blood circulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2512147A1 CA2512147A1 (en) | 2004-07-15 |
| CA2512147C true CA2512147C (en) | 2014-09-16 |
Family
ID=32479738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2512147A Expired - Lifetime CA2512147C (en) | 2002-12-31 | 2003-12-12 | Aqueous extract of red vine leave and use thereof for improving blood circulation |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1435242A1 (enExample) |
| JP (1) | JP2006516542A (enExample) |
| AT (1) | ATE545426T1 (enExample) |
| AU (1) | AU2003290031A1 (enExample) |
| BR (1) | BR0317895A (enExample) |
| CA (1) | CA2512147C (enExample) |
| CY (1) | CY1112766T1 (enExample) |
| DK (1) | DK1581239T3 (enExample) |
| ES (1) | ES2382461T3 (enExample) |
| MX (1) | MXPA05007095A (enExample) |
| PE (1) | PE20040932A1 (enExample) |
| PL (1) | PL215868B1 (enExample) |
| PT (1) | PT1581239E (enExample) |
| RU (1) | RU2341280C2 (enExample) |
| SI (1) | SI1581239T1 (enExample) |
| TW (1) | TW200501973A (enExample) |
| UA (1) | UA85548C2 (enExample) |
| WO (1) | WO2004058280A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101296693B (zh) | 2005-10-26 | 2012-07-04 | 花王株式会社 | 持久力提高剂 |
| US20110200539A1 (en) * | 2007-08-31 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Sprayable composition comprising extract of red vine leaves |
| DE102008012908A1 (de) * | 2008-03-06 | 2009-09-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methode zum anti-inflammatorischen und anti-ödematösen Schutz von explantiertem biologischen Material bis zu seiner Transplantation in Patienten |
| JP2015224205A (ja) * | 2014-05-27 | 2015-12-14 | エスエス製薬株式会社 | 冷え症等の全身症状改善用経口組成物 |
| KR20200115927A (ko) * | 2019-03-29 | 2020-10-08 | 주식회사 유니베라 | 포도잎 추출물 및 병풀 추출물을 포함하는 정맥순환 장애 개선용 조성물 |
| JP7262079B2 (ja) * | 2019-06-27 | 2023-04-21 | 廉士 澤田 | 生体センサ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE617039A (enExample) * | 1961-05-13 | |||
| FR2276059A1 (fr) * | 1974-06-25 | 1976-01-23 | Agronomique Inst Nat Rech | Procede d'extraction de pigments vegetaux de la classe des facteurs vitaminiques p a partir de plantes en contenant |
| JP2001122791A (ja) * | 1999-10-20 | 2001-05-08 | Boehringer Ingelheim Internatl Gmbh | 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤 |
-
2002
- 2002-12-31 EP EP02029107A patent/EP1435242A1/en not_active Withdrawn
-
2003
- 2003-12-12 DK DK03782385.3T patent/DK1581239T3/da active
- 2003-12-12 ES ES03782385T patent/ES2382461T3/es not_active Expired - Lifetime
- 2003-12-12 BR BR0317895-1A patent/BR0317895A/pt not_active Application Discontinuation
- 2003-12-12 PL PL378344A patent/PL215868B1/pl unknown
- 2003-12-12 UA UAA200507494A patent/UA85548C2/ru unknown
- 2003-12-12 WO PCT/EP2003/014147 patent/WO2004058280A1/en not_active Ceased
- 2003-12-12 AU AU2003290031A patent/AU2003290031A1/en not_active Abandoned
- 2003-12-12 JP JP2004562740A patent/JP2006516542A/ja active Pending
- 2003-12-12 CA CA2512147A patent/CA2512147C/en not_active Expired - Lifetime
- 2003-12-12 RU RU2005124164/15A patent/RU2341280C2/ru active
- 2003-12-12 PT PT03782385T patent/PT1581239E/pt unknown
- 2003-12-12 MX MXPA05007095A patent/MXPA05007095A/es active IP Right Grant
- 2003-12-12 AT AT03782385T patent/ATE545426T1/de active
- 2003-12-12 EP EP03782385A patent/EP1581239B1/en not_active Expired - Lifetime
- 2003-12-12 SI SI200332136T patent/SI1581239T1/sl unknown
- 2003-12-29 TW TW092137312A patent/TW200501973A/zh unknown
-
2004
- 2004-01-05 PE PE2004000018A patent/PE20040932A1/es not_active Application Discontinuation
-
2012
- 2012-05-08 CY CY20121100426T patent/CY1112766T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1581239B1 (en) | 2012-02-15 |
| CA2512147A1 (en) | 2004-07-15 |
| CY1112766T1 (el) | 2016-02-10 |
| DK1581239T3 (da) | 2012-06-11 |
| UA85548C2 (ru) | 2009-02-10 |
| EP1581239A1 (en) | 2005-10-05 |
| TW200501973A (en) | 2005-01-16 |
| JP2006516542A (ja) | 2006-07-06 |
| PE20040932A1 (es) | 2004-12-31 |
| ATE545426T1 (de) | 2012-03-15 |
| BR0317895A (pt) | 2005-12-06 |
| MXPA05007095A (es) | 2005-09-12 |
| RU2005124164A (ru) | 2006-03-20 |
| ES2382461T3 (es) | 2012-06-08 |
| PT1581239E (pt) | 2012-05-11 |
| PL378344A1 (pl) | 2006-03-20 |
| WO2004058280A1 (en) | 2004-07-15 |
| RU2341280C2 (ru) | 2008-12-20 |
| PL215868B1 (pl) | 2014-02-28 |
| SI1581239T1 (sl) | 2012-06-29 |
| EP1435242A1 (en) | 2004-07-07 |
| AU2003290031A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001122791A (ja) | 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤 | |
| KR101189108B1 (ko) | 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물 | |
| CA2512147C (en) | Aqueous extract of red vine leave and use thereof for improving blood circulation | |
| US20040151794A1 (en) | Method of improvement of blood circulation | |
| US20040151769A1 (en) | Film coated tablet containing an extract of red vine leaves | |
| EP1581195B1 (en) | Film coated tablet comprising an extract of red vine leaves | |
| CN105596777A (zh) | 一种疏通血管降血压的中药 | |
| KR100949482B1 (ko) | 주목과 뽕나무 추출물을 이용한 당뇨 또는 고혈압 치료용 약학 조성물 및 이의 제조 방법 | |
| EP1368045B1 (en) | Process for obtention of decoctions of vitis labrusca and vitis vinifera skins | |
| KR100850503B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 성기능 개선용조성물 | |
| KR100712659B1 (ko) | 당뇨병 및 이로 인한 합병증 치료 및 예방용 한약조성물 | |
| KR100894029B1 (ko) | 인삼 꽃을 원료로 하는 당뇨의 예방을 위한 약학 조성물 및 치료를 위한 약학 조성물 | |
| KR20240150190A (ko) | 인삼 추출물을 유효성분으로 포함하는 비알코올성 지방간염 예방 또는 치료용 조성물 | |
| ZA200505059B (en) | Film coated tablet comprising an extract of red vine leaves | |
| KR20190000651A (ko) | 백삼 추출물을 유효성분으로 포함하는 당뇨병성 혈류장애의 예방, 개선 또는 치료용 조성물 | |
| HK1089942A (en) | Film coated tablet comprising an extract of red vine leaves | |
| CN104888126A (zh) | 一种治疗冠心病的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20231212 |